Evaluation of GATA3 and GCDFP15 Expression in Triple Negative Breast Cancers.
Breast cancer
GATA-3
GCDFP-15
Triple-negative breast cancer
Journal
Iranian journal of pathology
ISSN: 1735-5303
Titre abrégé: Iran J Pathol
Pays: Iran
ID NLM: 101515128
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
10
2022
accepted:
29
12
2022
medline:
29
6
2023
pubmed:
29
6
2023
entrez:
29
6
2023
Statut:
ppublish
Résumé
Breast cancer is one of the most common cancers in the world. There are some different types of breast cancer and triple-negative breast cancer is the type in which no receptors for estrogen, progesterone, and human epidermal growth factor receptor-2 are expressed. Identifying factors that can facilitate the diagnosis of triple-negative breast cancer is important. In this study, we decided to investigate the expression of GATA3 and GCDFP15 genes in triple-negative breast cancers. This is a retrospective descriptive-analytical study that was performed on 50 specimens of samples of triple-negative breast cancer. Data including age and sex, tumor grade, tumor size, types of invasion, GATA-3, and GCDFP-15 were assessed. The mean age of the patients was 48.3±14.17 years. Of the total specimens, 46% were positive for GCDFP15 and 90% were positive for GATA-3. The intensity of GATA3 was evaluated and it was observed that 33(73.3%) of the cells were strongly stained and 12(26.7%) were weakly stained. There were no relationships between GATA-3 and GCDFP-15 with tumor characteristics. GATA-3 and GCDFP-15 may serve as diagnostic markers for triple-negative breast cancers and GATA-3 seems to be more reliable.
Sections du résumé
Background & Objective
UNASSIGNED
Breast cancer is one of the most common cancers in the world. There are some different types of breast cancer and triple-negative breast cancer is the type in which no receptors for estrogen, progesterone, and human epidermal growth factor receptor-2 are expressed. Identifying factors that can facilitate the diagnosis of triple-negative breast cancer is important. In this study, we decided to investigate the expression of GATA3 and GCDFP15 genes in triple-negative breast cancers.
Methods
UNASSIGNED
This is a retrospective descriptive-analytical study that was performed on 50 specimens of samples of triple-negative breast cancer. Data including age and sex, tumor grade, tumor size, types of invasion, GATA-3, and GCDFP-15 were assessed.
Results
UNASSIGNED
The mean age of the patients was 48.3±14.17 years. Of the total specimens, 46% were positive for GCDFP15 and 90% were positive for GATA-3. The intensity of GATA3 was evaluated and it was observed that 33(73.3%) of the cells were strongly stained and 12(26.7%) were weakly stained. There were no relationships between GATA-3 and GCDFP-15 with tumor characteristics.
Conclusion
UNASSIGNED
GATA-3 and GCDFP-15 may serve as diagnostic markers for triple-negative breast cancers and GATA-3 seems to be more reliable.
Identifiants
pubmed: 37383162
doi: 10.30699/IJP.2023.561917.2969
pmc: PMC10293598
doi:
Types de publication
Journal Article
Langues
eng
Pagination
90-95Déclaration de conflit d'intérêts
The authors declared no conflict of interest.
Références
Front Oncol. 2019 May 07;9:354
pubmed: 31134153
Cancer Med. 2019 Feb;8(2):554-563
pubmed: 30632300
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Clin Oncol. 2006 Dec 20;24(36):5652-7
pubmed: 17116942
Am J Clin Pathol. 2014 May;141(5):648-55
pubmed: 24713735
N Engl J Med. 2010 Nov 11;363(20):1938-48
pubmed: 21067385
Cancers (Basel). 2021 Aug 25;13(17):
pubmed: 34503097
CA Cancer J Clin. 2018 Nov;68(6):488-505
pubmed: 30328620
Mod Pathol. 2010 May;23(5):654-61
pubmed: 20173733
Ann Diagn Pathol. 2017 Feb;26:1-5
pubmed: 28038704
Am J Surg Pathol. 2019 Mar;43(3):293-302
pubmed: 30628926
Breast Cancer (Dove Med Press). 2016 May 20;8:93-107
pubmed: 27284266
J Cancer Res Ther. 2017 Oct-Dec;13(6):947-950
pubmed: 29237956
Hum Pathol. 2014 Nov;45(11):2225-32
pubmed: 25150746
Turk Patoloji Derg. 2014;30(1):18-22
pubmed: 24272937
BMC Cancer. 2014 Jul 28;14:546
pubmed: 25070172
BMC Cancer. 2016 Sep 15;16(1):734
pubmed: 27634735
Cancer. 2020 May 15;126 Suppl 10:2339-2352
pubmed: 32348573
Cancers (Basel). 2015 May 22;7(2):908-29
pubmed: 26010605
Clin Cancer Res. 2004 Aug 15;10(16):5367-74
pubmed: 15328174
Clin Breast Cancer. 2010 Aug 1;10(4):294-300
pubmed: 20705562
Diagn Cytopathol. 2016 Sep;44(9):731-6
pubmed: 27338760
Histopathology. 2013 Jan;62(2):267-74
pubmed: 22963676
Medicina (Kaunas). 2021 Jan 12;57(1):
pubmed: 33445543
Pleura Peritoneum. 2017 Sep 01;2(3):143-148
pubmed: 30911644
Cureus. 2016 Dec 9;8(12):e924
pubmed: 28090417
Hum Pathol. 2016 Jan;47(1):26-31
pubmed: 26527523
Breast Cancer Res Treat. 2018 May;169(1):25-32
pubmed: 29340880
Adv Anat Pathol. 2013 Sep;20(5):352-60
pubmed: 23939152
J Clin Oncol. 2008 Jul 1;26(19):3153-8
pubmed: 18490649